WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Statistics

Total Valuation

WuXi Biologics has a market cap or net worth of HKD 100.29 billion. The enterprise value is 98.05 billion.

Market Cap	100.29B
Enterprise Value	98.05B

Important Dates

The next estimated earnings date is Wednesday, August 20, 2025.

Earnings Date	Aug 20, 2025
Ex-Dividend Date	n/a

Share Statistics

WuXi Biologics has 4.07 billion shares outstanding. The number of shares has decreased by -2.80% in one year.

Current Share Class	4.07B
Shares Outstanding	4.07B
Shares Change (YoY)	-2.80%
Shares Change (QoQ)	-1.35%
Owned by Insiders (%)	0.54%
Owned by Institutions (%)	36.21%
Float	3.46B

Valuation Ratios

The trailing PE ratio is 29.52 and the forward PE ratio is 20.80. WuXi Biologics's PEG ratio is 1.33.

PE Ratio	29.52
Forward PE	20.80
PS Ratio	5.05
PB Ratio	2.07
P/TBV Ratio	2.37
P/FCF Ratio	73.19
P/OCF Ratio	18.06
PEG Ratio	1.33

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.30, with an EV/FCF ratio of 71.55.

EV / Earnings	27.45
EV / Sales	4.93
EV / EBITDA	15.30
EV / EBIT	20.09
EV / FCF	71.55

Financial Position

The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.11.

Current Ratio	2.73
Quick Ratio	1.98
Debt / Equity	0.11
Debt / EBITDA	0.82
Debt / FCF	3.84
Interest Coverage	29.10

Financial Efficiency

Return on equity (ROE) is 8.82% and return on invested capital (ROIC) is 5.79%.

Return on Equity (ROE)	8.82%
Return on Assets (ROA)	5.05%
Return on Invested Capital (ROIC)	5.79%
Return on Capital Employed (ROCE)	9.48%
Revenue Per Employee	1.58M
Profits Per Employee	284,012
Employee Count	12,575
Asset Turnover	0.33
Inventory Turnover	6.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +128.03% in the last 52 weeks. The beta is 0.55, so WuXi Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	+128.03%
50-Day Moving Average	23.32
200-Day Moving Average	19.00
Relative Strength Index (RSI)	61.53
Average Volume (20 Days)	35,252,890

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, WuXi Biologics had revenue of HKD 19.87 billion and earned 3.57 billion in profits. Earnings per share was 0.83.

Revenue	19.87B
Gross Profit	8.14B
Operating Income	4.88B
Pretax Income	5.14B
Net Income	3.57B
EBITDA	6.22B
EBIT	4.88B
Earnings Per Share (EPS)	0.83

Balance Sheet

The company has 11.40 billion in cash and 5.26 billion in debt, giving a net cash position of 6.14 billion or 1.51 per share.

Cash & Cash Equivalents	11.40B
Total Debt	5.26B
Net Cash	6.14B
Net Cash Per Share	1.51
Equity (Book Value)	48.40B
Book Value Per Share	10.84
Working Capital	15.91B

Cash Flow

In the last 12 months, operating cash flow was 5.55 billion and capital expenditures -4.18 billion, giving a free cash flow of 1.37 billion.

Operating Cash Flow	5.55B
Capital Expenditures	-4.18B
Free Cash Flow	1.37B
FCF Per Share	0.34

Margins

Gross margin is 40.97%, with operating and profit margins of 24.55% and 17.97%.

Gross Margin	40.97%
Operating Margin	24.55%
Pretax Margin	25.89%
Profit Margin	17.97%
EBITDA Margin	31.32%
EBIT Margin	24.55%
FCF Margin	6.89%

Dividends & Yields

WuXi Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.80%
Shareholder Yield	n/a
Earnings Yield	3.56%
FCF Yield	1.37%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.

Last Split Date	Nov 16, 2020
Split Type	Forward
Split Ratio	3

Scores

WuXi Biologics has an Altman Z-Score of 4.46.

Altman Z-Score	4.46
Piotroski F-Score	n/a